US telehealth company Hims & Hers posts strong Q1 revenue

Hims & Hers Health’s shares declined in after-hours trading following its first-quarter earnings report, which included a weaker revenue outlook for Q2.

The company reported US$586 million in first-quarter revenue, surpassing analysts’ expectations of US$538 million.

Earnings per share were 20 cents, above the forecasted 12 cents. Net income rose to US$49.5 million, up from US$11.1 million a year earlier.

For Q2, Hims & Hers projects revenue between US$530 million and US$550 million, below the US$564.6 million anticipated by analysts.

🔗 Source: CNBC

🧠 Food for thought

1️⃣ Telehealth platforms evolve into full healthcare ecosystems

Hims & Hers’ expansion beyond basic telehealth consultations shows how digital health companies are evolving into comprehensive healthcare platforms.

The company’s 53% increase in monthly revenue per subscriber (from $55 to $84) demonstrates successful monetization beyond initial consultations 1.

Their subscriber base has grown to 2.4 million (up 38% year-over-year), with 1.4 million utilizing personalized health solutions, showing how telehealth is becoming integrated into regular healthcare routines 2.

CEO Andrew Dudum’s emphasis on “wider collaboration across the industry, inclusive of pharmaceutical players, innovative leaders in diagnostic and preventative testing, and world-class providers” reveals the strategy of becoming a healthcare hub rather than just a consultation service 3.

The hiring of Amazon veteran Nader Kabbani, who oversaw Amazon Pharmacy and PillPack acquisition, further signals this ecosystem ambition, bringing in expertise specifically in building integrated healthcare delivery systems 3.

2️⃣ Personalization in healthcare comes with economic tradeoffs

Hims & Hers’ financial performance reveals both the opportunities and challenges of scaling personalized healthcare.

While revenue grew 111% year-over-year to $586 million, the company’s gross margin simultaneously decreased from 82% to 73%, suggesting that delivering more personalized care may require accepting lower margins 1.

The company’s focus on expanding from “hundreds to thousands of personalized offerings” demonstrates the industry’s move toward tailored treatment plans rather than one-size-fits-all approaches 4.